Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
Version 2 2023-09-27, 08:26
Version 1 2023-09-18, 09:51
media
posted on 2023-09-27, 08:26 authored by Adis Journals on Behalf of, Martin Kolb, Kevin R. Flaherty, Rafael Silva, Antje Prasse, Carlo Vancheri, Mueller, Heiko, Kamila Sroka-Saidi, Athol U. Wells, on behalf of the INBUILD trial investigators
Article full text
The above slide deck represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
